scPharmaceuticals (NASDAQ:SCPH) Now Covered by Maxim Group

Investment analysts at Maxim Group started coverage on shares of scPharmaceuticals (NASDAQ:SCPHGet Rating) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s target price indicates a potential upside of 101.61% from the company’s current price.

Several other equities research analysts have also issued reports on SCPH. SVB Leerink raised their target price on shares of scPharmaceuticals to $6.00 and gave the stock a “market perform” rating in a report on Tuesday, May 17th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of scPharmaceuticals in a report on Wednesday, July 13th.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH opened at $4.96 on Tuesday. scPharmaceuticals has a 52 week low of $3.48 and a 52 week high of $7.24. The stock has a market capitalization of $135.76 million, a P/E ratio of -4.72 and a beta of 0.39. The firm has a fifty day simple moving average of $4.87 and a two-hundred day simple moving average of $4.98. The company has a quick ratio of 4.81, a current ratio of 4.81 and a debt-to-equity ratio of 0.10.

scPharmaceuticals (NASDAQ:SCPHGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. On average, analysts expect that scPharmaceuticals will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On scPharmaceuticals

Several institutional investors have recently made changes to their positions in SCPH. AIGH Capital Management LLC lifted its holdings in scPharmaceuticals by 1.7% during the 1st quarter. AIGH Capital Management LLC now owns 1,396,724 shares of the company’s stock valued at $7,933,000 after buying an additional 23,600 shares in the last quarter. Worth Venture Partners LLC lifted its holdings in scPharmaceuticals by 4.7% during the 1st quarter. Worth Venture Partners LLC now owns 348,425 shares of the company’s stock valued at $1,979,000 after buying an additional 15,778 shares in the last quarter. Belvedere Trading LLC lifted its holdings in scPharmaceuticals by 48.7% during the 2nd quarter. Belvedere Trading LLC now owns 239,219 shares of the company’s stock valued at $1,270,000 after buying an additional 78,337 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in scPharmaceuticals by 7.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 103,534 shares of the company’s stock valued at $588,000 after buying an additional 6,787 shares in the last quarter. Finally, Simplex Trading LLC lifted its holdings in scPharmaceuticals by 2,366.0% during the 1st quarter. Simplex Trading LLC now owns 23,156 shares of the company’s stock valued at $131,000 after buying an additional 22,217 shares in the last quarter. Institutional investors own 72.84% of the company’s stock.

scPharmaceuticals Company Profile

(Get Rating)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.